Laboratory of General Biochemistry and Physical Pharmacy

Félix Sauvage

Félix Sauvage

 

 

 

 

 

Contact

Laboratory for General Biochemistry and Physical Pharmacy
Ghent University
Ottergemsesteenweg 460
9000 Gent
Belgium
Tel: 0032 9 264 80 47 (secretary)
Tel: 0032 9 264 80 95 (direct)
E-mail:

Biography

Félix Sauvage received his pharmacy degree in 2013 from the University of Rouen, France. The same year, he obtained his Ms. Sc. (Pharmaceutical Technology and Biopharmaceutics, University Paris-Saclay) and a fellowship from the French Ministry of Higher Education and Research. He joined the Institut-Galien Paris-Sud (University Paris Saclay, France) for a Ph.D. under the supervision of Drs Gillian Barratt and Juliette Vergnaud-Gauduchon. His research mainly focused on the formulation of liposomes containing a hsp90 inhibitor (6BrCaQ) and on the anti-cancer effects of this system in vitro and in vivo in an orthotopic breast cancer model. He also worked on liposomes for drug delivery to mitochondria and particularly on the biophysical interactions occurring between mitochondrial targeting agents and liposomal bilayers. In 2017, Félix Sauvage joined the Laboratory of General Biochemistry and Physical Pharmacy at Ghent University as a postdoctoral research scientist.

Summary of research projects

The aim of the project is to use several biophysical techniques (FRAP, single particle tracking) to improve the treatment of several ocular diseases, therapeutic protein delivery and to understand the role of the viscosity in the vitreous. This work is divided in several parts:

-          Harnessing gold nanoparticles to improve laser-assisted (nd:YAG) treatment of eye floaters through Vapor Nanobubbles formation in the vitreous.

-          Mapping the viscosity in the vitreous using fluorescent probes to correlate viscosity changes with age and pathological conditions.

-          Using fluorescent probes of different molecular weights to assess the porosity of retinal blood vessels in pathological conditions (e.g.: diabetes).

-          Understanding therapeutic protein aggregation (e.g: antibodies) occurring in the vitreous to improve treatments of eye diseases and their compliance.